Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03860857 · ClinicalTrials.gov registry record · Phase 3
Biomarker Exploration in Aging, Cognition and Neurodegeneration
A Phase 3 study of Alzheimer Disease and Cognitive Impairment, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT03860857: Recruiting Phase 3 study of Alzheimer Disease and Cognitive Impairment, sponsored by University of California, Irvine.
NCT03860857 is a Phase 3 study of Alzheimer Disease and Cognitive Impairment that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 300 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03860857, a Phase 3 study of Alzheimer Disease and Cognitive Impairment, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to understand the factors that underlie changes in thinking and memory with increasing age. The investigators will test the usefulness of MRI, PET, and cognitive testing in detecting subtle changes in the brain that precede cognitive decline. An addendum to this study includes additional PET scans to examine the relationship between tau protein in the brain and cognitive decline. Tau is a protein that is known to form tangles in the areas of the brain important for memory, and these tau tangles are a hallmark of Alzheimer's disease. This sub-study research aims to look at the tau accumulation in the brain using an investigational drug called MK-6240, which is a radio tracer that gets injected prior to a positron emission tomography (PET) scan.
Primary Outcome
A measure of cognitive/clinical decline
Conditions Studied
Interventions
- OTHER MRI
- RADIATION Amyloid PET scan
- DRUG Tau PET scan using MK-6240
- BEHAVIORAL Neurocognitive testing
Study Locations (1)
California
- University of California, Irvine - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2027-12-22 |
| Phase | Phase 3 |
What NCT03860857 shows while recruiting
NCT03860857 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (89% lower).
The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 4 interventions - of which MRI is the first listed.
NCT03860857 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03860857 about?
NCT03860857 is a clinical study titled "Biomarker Exploration in Aging, Cognition and Neurodegeneration". The purpose of this research study is to understand the factors that underlie changes in thinking and memory with increasing age. The investigators will test the usefulness of MRI, PET, and cognitive testing in detecting subtle changes in the brain that precede cognitive decline. An addendum to this...
What is the current status of trial NCT03860857?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2018-05-01. Estimated completion is 2027-12-22.
What conditions does trial NCT03860857 study?
This clinical trial studies the following conditions: Alzheimer Disease, Cognitive Impairment, Cognitive Decline.
What interventions are being tested in trial NCT03860857?
The interventions under investigation include: MRI (OTHER), Amyloid PET scan (RADIATION), Tau PET scan using MK-6240 (DRUG), Neurocognitive testing (BEHAVIORAL).
Who is sponsoring clinical trial NCT03860857?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03860857 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03860857's enrollment target sits among peer trials
300 79th of 306 higher than 225 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Epidemiology and Biomarker Study in Alzheimer's Disease
RECRUITING · Phase 3
-
[18F]PI-2620 Phase 3 Histopathological Study
RECRUITING · Phase 3
-
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
RECRUITING · Phase 3
-
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
RECRUITING · Phase 3
-
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI